Tempest Therapeutics
TPST
80 hedge funds and large institutions have $206M invested in Tempest Therapeutics in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 14 closing their positions.
38% more capital invested
Capital invested by funds: $149M → $206M (+$56.9M)
35% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 17
6% less funds holding
Funds holding: 85 → 80 (-5)
35% less call options, than puts
Call options by funds: $160K | Put options by funds: $247K
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$2.86M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$1.79M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.18M |
| 4 |
D.E. Shaw & Co
New York
|
+$778K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$633K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.47M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$961K |
| 4 |
Jennison Associates
New York
|
-$760K |
| 5 |
Millennium Management
New York
|
-$712K |
TPST Hedge Fund Activity: Q3 2016 in Review
80 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2016, worth a combined $206M — up 38% from $149M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TPST and 9 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 23 added.
The largest buyer was Portolan Capital Management, adding an estimated $2.86M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.3M sold.
- 80 institutional investors held Tempest Therapeutics (TPST) as of Q3 2016, down from 85 in Q2 2016.
- Funds reported $206M of Tempest Therapeutics stock for Q3 2016, up 38% quarter-over-quarter.
- 9 funds opened new Tempest Therapeutics positions in Q3 2016 and 14 closed out, a net change of -5 holders.
- The largest Tempest Therapeutics buyer in Q3 2016 was Portolan Capital Management, an estimated $2.86M added.
- The largest Tempest Therapeutics seller in Q3 2016 was JP Morgan Chase, an estimated $2.3M sold.
Based on aggregated 13F filings for Q3 2016.